| 刘飞,赵文英,陈小雪.甲磺酸阿帕替尼治疗晚期恶性肿瘤 45例[J].安徽医药,2021,25(3):593-595. |
| 甲磺酸阿帕替尼治疗晚期恶性肿瘤 45例 |
| Treatment of 45 patients with advanced malignant tumors with apatinib mesylate |
| |
| DOI：10.3969/j.issn.1009-6469.2021.03.040 |
| 中文关键词: 甲磺酸阿帕替尼 肿瘤 分子靶向治疗 疗效 安全性 |
| 英文关键词: Apatinib mesylate Neoplasms Molecular targeted therapy Efficacy Safety |
| 基金项目:安徽省自然科学基金( 1708085MH202) |
|
| 摘要点击次数: 1459 |
| 全文下载次数: 505 |
| 中文摘要: |
| 目的探讨在晚期恶性肿瘤病人中应用甲磺酸阿帕替尼的疗效及安全性。方法选择 2017年 8月 1日至 2019年 7月 31日池州市第二人民医院接受单药甲磺酸阿帕替尼靶向治疗或联合化疗方案的 51例晚期恶性肿瘤病人进行回顾性分析，对近期疗效及生存状况进行评估，并观察不良反应的发生情况。结果 45例病人可评估疗效，无完全缓解( CR)病例，部分缓解(PR)12例，稳定( SD)15例和进展( PD)18例，客观缓解率( ORR)和疾病控制率( DCR)分别为 26.67%和 60.00%，中位无进展生存( PFS)4个月，中位总生存( OS)7个月；不良反应有高血压( 44.44%)、蛋白尿( 31.11%)、手足综合征( 26.67%)、胆红素升高 |
| 英文摘要: |
| Objective To investigate the efficacy and safety of apatinib mesylate in patients with advanced malignant tumors. Meth? ods 51 patients with advanced malignant tumors were selected for retrospective analysis from August 1, 2017 to July 31, 2019 in Chi?zhou Second People′s Hospital. They were treated with single drug apatinib mesylate, or combined chemotherapy. The short-term effica? cy and survival status were evaluated, and the occurrence of adverse reactions was observed. Results 45 patients were evaluated forthe curative effect. There were no CR cases, 12 PR cases, 15 SD cases and 18 PD cases. ORR and DCR were 26.67% and 60.0% re?spectively. The median PFS was 4 months and the median OS was 7 months. Adverse reactions included hypertension(44.44%), protein?uria(31.11%), hand-foot syndrome(26.67%), bilirubin elevation(22.22%), transaminase elevation(20.00%), and gastrointestinal reac?tions(11.11%), etc. Most of them were 1-2 levels, and the incidence of severe adverse reactions was low. Conclusion Apatinib mesyl? ate is effective and safe in the treatment of advanced malignant tumors. The patient can tolerate. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
